Cyclic PNA Monomers for Solubility and Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Peptide nucleic acids (PNAs) face challenges with low water solubility and inefficient cellular uptake due to their hydrophobic nature, which hinders their ability to effectively cross cellular membranes and bind to nucleic acids, limiting their therapeutic potential, especially in cancer treatment.
Innovation Solution
Incorporation of cyclic structural moieties such as tetrahydrofuran, pyrrolidinium, or N-methyl pyrrolidine into the C2-C3 position of PNA monomers enhances water solubility and binding affinity to nucleic acids, improving their delivery and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PNA structure is used, then binding stability to nucleic acids is improved, but water solubility deteriorates
Solution Approach 1:
The patent introduces charged groups at specific local positions (N-terminus and/or C-terminus) of the PNA molecule while keeping the backbone structure intact. This localized modification approach maintains the central binding stability function while adding solubility enhancement at the terminal regions, resolving the contradiction between binding stability and water solubility.
Solution Approach 2:
The patent creates composite PNA structures by combining the conventional PNA backbone with additional charged functional groups or moieties at the terminal positions. This composite approach integrates the stable binding properties of PNA with the enhanced solubility characteristics of charged groups, achieving both improved binding stability and water solubility simultaneously.
2Reliability
If conventional PNA structure is used, then binding stability to nucleic acids is improved, but cellular uptake efficiency deteriorates
Solution Approach 1:
The patent applies local modification at the terminal positions of PNA with charged groups that facilitate cellular interaction and uptake. This localized approach preserves the core binding function while enhancing cellular penetration capability through the modified terminal regions, resolving the contradiction between binding stability and cellular uptake efficiency.
Solution Approach 2:
The patent develops composite PNA structures incorporating charged functional groups or cell-penetrating moieties at the terminals. This composite design combines the stable nucleic acid binding properties of PNA with enhanced cellular uptake capabilities provided by the charged terminal groups, achieving both binding stability and improved cellular delivery.
3Force
If PNA length is increased, then binding strength is improved, but specificity deteriorates
Solution Approach 1:
The patent modifies the terminal parameters of PNA by adding charged groups that enhance binding strength through electrostatic interactions. This parameter change at the terminal positions provides additional binding force without requiring extension of the oligonucleotide sequence, thereby maintaining sequence specificity while improving overall binding strength.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified PNAs exhibit improved solubility and stronger binding affinity, enabling more effective cellular uptake and target gene inhibition, potentially leading to enhanced cancer treatment outcomes.
Implementation Method 1
Incorporation of cyclic structural moieties such as tetrahydrofuran, pyrrolidinium, or N-methyl pyrrolidine into the C2-C3 position of PNA monomers enhances water solubility
Implementation Method 2
Incorporation of cyclic structural moieties such as tetrahydrofuran, pyrrolidinium, or N-methyl pyrrolidine into the C2-C3 position of PNA monomers enhances water solubility and binding affinity to nucleic acids
Data Source
AI summary
The present disclosure provides peptide nucleic acids (PNAs) including cyclic structural moieties such as tetrahydrofuran, pyrrolidinium, pyrrolidine, or N-methyl pyrrolidine, which have surprisingly improved the water solubility and binding affinity of PNA oligomers to ribose-phosphate nucleic acid oligomers. Pharmaceutical compositions including the disclosed PNAs, synthetic methods thereof, and methods of use thereof are also disclosed.